The pattern of new-onset AF differed between ranolazine vs. placebo : clinically insignificant AF ( five patients in ranolazine vs. seven in placebo ) , paroxysmal AF ( 18 vs. 48 patients ) , and predominantly chronic AF ( 28 vs. 20 patients , three-way P < 0.01 ) .